CompoAtlas

Senna Tablets 8.6 mg

Natural health product licensed in Canada

Licence holder
9113657 Canada Inc.
NPN or DIN-HM
80125892
Status
Active licence
Licence date
1 August 2023
Revision date
Not provided
Form
Comprimé
Route of administration
Orale
Application type
Générale (non traditionelle)

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Senna alexandrina5 mgNot calculated
Senna alexandrina

Potency : 3.6 mg Hydroxyanthracene derivatives

3.6 mgNot calculated

Non-medicinal ingredients

Maltodextrine, Stéarate de magnésium, Cellulose microcristalline, Amidon de maïs

PopulationAgeQuantity per servingFrequency
Adolescents et adultesminimum: 12 years5 Comprimé1 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

(Traditionally used in Herbal Medicine as a) stimulant laxative. (Used in Herbal Medicine as a) stimulant laxative to promote bowel movement and short-term relief of occasional constipation. (Used in Herbal Medicine for the) short-term relief of occasional constipation. (Used in Herbal Medicine to) promote(s) bowel movement (by direct action on the large intestine).

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

No French warning text available in the imported data.

Warnings are available in English on the official record.

Source

Official Health Canada record, licence 80125892

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Senna alexandrina
    Read the warning, when it applies and the studies cited

    SENNA - SENNA ALEXANDRINA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2018a,b; Brinker 2010; Blumenthal et al. 2000; WHO 1999).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2018a,b; Brinker 2010; Blumenthal et al. 2000; WHO 1999).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (EMA 2018a,b; Brinker 2010; Blumenthal et al. 2000).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2018a,b; Gardner and McGuffin 2013; Brinker 2010; WHO 1999).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy or diarrhoea occurs (EMA 2018a,b; Blumenthal et al. 2000; WHO 1999).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 26 July 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line